posted on Aug, 16 2015 @ 08:40 AM
Approved in 2010 by US FDA and late 2015 by IRN FDO , the drug now opens a new chapter for patients with metastatic breast cancer who previously have
tried 2 drugs and failed .
the dramatic and promising results prompted FDA to take an extraordinary measure and approve it immediately . FDO approved the drug later in 2015
after more extensive research .
Eribulin which is the generic name for the drug "Halaven" .
most common adverse effects are : 1-neutropenia : that is the lowered count in white blood cells 2- lowered RBC count 3- alopecia : the falling of
hair 4-neuropathy : some problems with nerves in extremities and other places which causes tingling , ....
5-long Q-T syndrome : heartbeat changes which can be fatal in very extreme forms 6- constipation
these are the most common adverse effects . as you might know these drugs work by lowering the turnover (the reproduction) in all body cells esp.
cancer cells . why ? because cancer cells reproduce more .
in my own experience this drug had acceptable efficacy and lower adverse effects compared to other drugs available on the market which makes it a
viable option .